State Street
ZNTL icon

State Street’s Zentalis Pharmaceuticals ZNTL Stock Holding History

State Street’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$584K Sell
249,690
-22,100
-8% -$57.1K ﹤0.01% 3616
2025
Q4 		$367K Hold
271,790
– – ﹤0.01% 3760
2025
Q3 		$410K Hold
271,790
– – ﹤0.01% 3706
2025
Q2 		$315K Sell
271,790
-1,047,995
-79% -$1.38M ﹤0.01% 3720
2025
Q1 		$2.1M Buy
1,319,785
+30,800
+2% +$66.4K ﹤0.01% 3229
2024
Q4 		$3.91M Buy
1,288,985
+42,372
+3% +$139K ﹤0.01% 3064
2024
Q3 		$4.59M Sell
1,246,613
-1,805,779
-59% -$6.56M ﹤0.01% 3006
2024
Q2 		$12.5M Sell
3,052,392
-733,260
-19% -$8.19M ﹤0.01% 2431
2024
Q1 		$59.7M Sell
3,785,652
-631,404
-14% -$8.68M ﹤0.01% 1629
2023
Q4 		$66.9M Buy
4,417,056
+1,713,696
+63% +$25M ﹤0.01% 1542
2023
Q3 		$54.2M Sell
2,703,360
-449,554
-14% -$11.4M ﹤0.01% 1574
2023
Q2 		$88.9M Buy
3,152,914
+320,891
+11% +$7.7M ﹤0.01% 1301
2023
Q1 		$48.7M Sell
2,832,023
-252,114
-8% -$5.11M ﹤0.01% 1666
2022
Q4 		$62.1M Buy
3,084,137
+233,963
+8% +$5.03M ﹤0.01% 1485
2022
Q3 		$61.7M Sell
2,850,174
-269,560
-9% -$7.37M ﹤0.01% 1455
2022
Q2 		$87.7M Buy
3,119,734
+1,039,294
+50% +$27.5M 0.01% 1253
2022
Q1 		$96M Buy
2,080,440
+734,024
+55% +$39.6M ﹤0.01% 1323
2021
Q4 		$113M Buy
1,346,416
+54,153
+4% +$4.19M 0.01% 1197
2021
Q3 		$86.1M Sell
1,292,263
-47,077
-4% -$2.72M ﹤0.01% 1397
2021
Q2 		$71.3M Sell
1,339,340
-129,851
-9% -$6.95M ﹤0.01% 1574
2021
Q1 		$63.7M Buy
1,469,191
+577,682
+65% +$24.9M ﹤0.01% 1565
2020
Q4 		$46.3M Buy
891,509
+729,915
+452% +$32.9M ﹤0.01% 1688
2020
Q3 		$5.28M Buy
161,594
+24,324
+18% +$852K ﹤0.01% 2752
2020
Q2 		$6.59M Buy
+137,270
New +$5.26M ﹤0.01% 2627

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

State Street's ZNTL Position: Q1 2026 in Review

State Street reduced its Zentalis Pharmaceuticals (ZNTL) stake by 8.1% in Q1 2026, selling an estimated $57.1K and leaving 249,690 shares worth $584K. The position accounts for ﹤0.01% of the portfolio, ranked #3616.

State Street first reported a position in ZNTL in Q2 2020 and has held it in 24 quarters since. The position peaked at $113M in Q4 2021. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • State Street held 249,690 shares of Zentalis Pharmaceuticals worth $584K as of Q1 2026.
  • State Street sold 22,100 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $57.1K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3616 holding.
  • State Street first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • State Street's Zentalis Pharmaceuticals position peaked at $113M in Q4 2021.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.